|Application ||WB, IHC-P, E|
|Calculated MW||50819 Da|
|Dilution||ELISA (1:10000), IHC-P (20 µg/ml), WB (1:500 - 1:1000),|
|Other Names||PLAGL1, Lost on transformation 1, LOT1, PLAG-like 1, LOT-1, ZAC tumor supressor, Zinc finger protein PLAGL1, Tumor supressor ZAC, ZAC, ZAC1|
|Target/Specificity||PLAGL1 Antibody detects endogenous levels of total PLAGL1 protein.|
|Reconstitution & Storage||PBS (without Mg2+, Ca2+), pH 7.4, 150 mM sodium chloride, 0.02% sodium azide, 50% glycerol. Store at -20°C for up to one year.|
|Precautions||PLAGL1 / ZAC Antibody (aa311-360) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Shows weak transcriptional activatory activity. Transcriptional regulator of the type 1 receptor for pituitary adenylate cyclase-activating polypeptide.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Shows weak transcriptional activatory activity. Transcriptional regulator of the type 1 receptor for pituitary adenylate cyclase-activating polypeptide.
Abdollahi A.,et al.Oncogene 14:1973-1979(1997).
Kas K.,et al.J. Biol. Chem. 273:23026-23032(1998).
Varrault A.,et al.Proc. Natl. Acad. Sci. U.S.A. 95:8835-8840(1998).
Bilanges B.,et al.Oncogene 20:1246-1253(2001).
Varrault A.,et al.Submitted (MAY-2001) to the EMBL/GenBank/DDBJ databases.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.